Study identification

PURI

https://redirect.ema.europa.eu/resource/46192

EU PAS number

EUPAS44973

Study ID

46192

Official title and acronym

A prospective, registry based, observational study to asses maternal, fetal and infant outcomes following exposure to lasmiditan

DARWIN EU® study

No

Study countries

United States

Study description

The purpose of the study is to prospectively evaluate pregnancy/fetal, maternal and infant outcomes through 12 months of age among women exposed to lasmiditan during pregnancy, as well as in a comparator group not exposed to lasmiditan.

Study status

Ongoing
Research institutions and networks

Institutions

Syneos Health
United Kingdom
First published:
06/03/2024
InstitutionNon-Pharmaceutical companyENCePP partner

Contact details

Nicole Kellier-Steele

Primary lead investigator
Study timelines

Date when funding contract was signed

Planned:
Actual:

Study start date

Planned:
Actual:

Date of final study report

Planned:
Sources of funding
Pharmaceutical company and other private sector 

More details on funding

Eli Lilly and Company
Study protocol
Initial protocol
English (399.88 KB - PDF)View document
Regulatory

Was the study required by a regulatory body?

Yes

Is the study required by a Risk Management Plan (RMP)?

Not applicable